Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Autologous adipose stem cell mitochondria** refers to mitochondria isolated from mesenchymal stem cells derived from a patient's own adipose tissue, typically obtained via liposuction. These mitochondria are transplanted into oocytes during intracytoplasmic sperm injection (ICSI) to supplement mitochondrial function, aiming to improve oocyte quality, embryo development rates, euploidy, and pregnancy outcomes, particularly in patients with recurrent pregnancy loss, advanced maternal age, or poor oocyte quality. The approach leverages the high mitochondrial content, activity, and glycolytic metabolism of adipose-derived stem cells (ADSCs) to restore oocyte bioenergetics, reduce oxidative stress, and enhance cytoplasmic Ca²⁺ regulation without ethical concerns of allogeneic donation. Early research and pilot clinical studies indicate safety and potential efficacy in boosting transferable embryo rates, clinical pregnancy, and live birth rates[2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous adipose stem cell mitochondria.